Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report) shot up 0.5% during trading on Monday . The company traded as high as $1.91 and last traded at $1.86. 56,539 shares changed hands during trading, a decline of 99% from the average session volume of 4,892,017 shares. The stock had previously closed at $1.85.
Salarius Pharmaceuticals Stock Performance
The firm’s fifty day moving average price is $1.92 and its 200 day moving average price is $1.80. The firm has a market cap of $2.95 million, a P/E ratio of -0.23 and a beta of 0.84.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
See Also
- Five stocks we like better than Salarius Pharmaceuticals
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Merck: 4 No-Brainer Reasons to Buy This Dip
- Conference Calls and Individual Investors
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- 3 Monster Growth Stocks to Buy Now
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
